BioForce Nanosciences Holdings, Inc. transitioned from manufacturing nano-measurement devices to becoming a provider of nutritional supplements, focusing on products like powders and beverages to promote a healthier lifestyle.

# Company Summary: BioForce Nanosciences Holdings, Inc.

## Business Focus
- Transitioned from manufacturing nano-particular measurement devices and molecular printers (technology owned by a subsidiary that filed for bankruptcy and was bought out by an unrelated third party) to becoming a provider of nutritional supplements.

## Current Mission and Business Model
- Aims to be a leading provider of:
  - Natural vitamins
  - Minerals
  - Other nutritional supplements
  - Powders
  - Beverages
- Focused on promoting a healthier lifestyle for active individuals across all age groups.

## Product Offerings
- **Main Product:** *BioForce Eclipse*—a private label nutritional powder supplement.
  - Contains amino acids, vitamins, plant-based proteins.
  - Promotes muscle growth, suitable for athletes and health-conscious consumers.
- **Additional Plans:**
  - Develop new supplement products.
  - Offer products through retail stores, gyms, health clubs, supermarkets, mass merchandisers, online stores (including Amazon), and direct sales via its website (www.bioforceeclipse.com).
  - Target markets include health food stores, sporting goods stores, retail pharmacies, hospitals, clinics, universities, nursing homes, prisons, and other healthcare facilities.

## Marketing Strategies
- Currently markets via social media and telemarketing.
- Plans to expand through B2B sales campaigns, direct marketing, industry trade shows, conventions, and affiliate marketing.
- Intends to increase brand awareness and expand throughout the U.S.
- Will pursue retail relationships and develop new markets, including environmentally friendly biodegradable packaging.

## Company Operations and Infrastructure
- Executive Office located in Virginia Beach, Virginia.
- No properties owned or rented; uses offices owned by Richard Kaiser.
- Currently employs three full-time employees:
  - Merle Ferguson (Chairman)
  - Richard Kaiser (CFO and Secretary)
  - Steve Gagnon (Co-CEO)
- No stock options outstanding as of December 31, 2024.

## Financial Overview (as of December 31, 2024)
- **Revenue:** $0 from vitamin supplement sales during 2024 and 2023.
- **Net Loss:** 
  - 2024: $490,437
  - 2023: $471,953
- **Assets:** $862 (mostly cash)
- **Liabilities:** $2,302,454 (including accounts payable, accrued expenses, and amounts due to related parties)
- **Stockholders’ Deficit:** 
  - $2,301,592 (as of December 31, 2024)
- **Shareholding:** 
  - 33,521,755 shares of common stock outstanding as of April 7, 2025.
  - Major shareholder Merle Ferguson owns 51.24% of the shares.

## Additional Notes
- The company’s operations are in a growth and development stage, with limited revenue and significant accumulated deficits.
- Has no material legal proceedings.
- Involved in various related-party transactions, including funding from key officers.
- Future plans involve expanding sales, brand recognition, and possibly creating new products beyond powders.
- Current marketing efforts are largely online; less emphasis on traditional advertising.
- Company’s financial position indicates ongoing dependency on debt and equity financing to sustain operations and implement its business plans.

BioForce Nanosciences Holdings, Inc. is a Nevada-based company that develops and sells nutritional supplements, focusing primarily on its flagship product, BioForce Eclipse.

# Summary of BioForce Nanosciences Holdings, Inc.

## Company Overview
BioForce Nanosciences Holdings, Inc. is a Nevada-based company that specializes in the development and sale of natural vitamins, minerals, and nutritional supplements. The company focuses on promoting a healthier lifestyle for active individuals across all age ranges through its product offerings, which include powders and beverages that complement dietary needs for active lifestyles.

## Business Model
- BioForce entered the supplement market around **2015** and subsequently shifted its business model to focus on nutrition supplements.
- The company's main product line is **BioForce Eclipse**, a nutritional powder that consists of a mixture of amino acids, key vitamins, and plant-based proteins, optimal for muscle growth.
- BioForce markets its products through various channels including social media, telemarketing, and aims to expand to B2B (Business to Business) sales and direct marketing campaigns.
- The product offerings target multiple retail channels, such as nutrition retailers, grocery stores, pharmacies, health clubs, and online platforms like Amazon.
- Although the company intends to broaden its portfolio beyond nutritional powder, it will maintain a focus on products that enhance the “BioForce Eclipse” brand.

## Financials
- As of December 31, 2023, BioForce reported **no revenue**, having sold **zero units** of its “BioForce Eclipse” supplement in both 2022 and 2023.
- The company had an **accumulated deficit** of **$160,629,729** and reported a **net loss** of **$471,953** for the year ended December 31, 2023.
- Total liabilities stood at approximately **$1,819,868**.
- The cash position was very low, with total current assets amounting to **$638** as of December 31, 2023.

## Employees and Management
- The company has **three full-time employees**:
  - **Merle Ferguson** - Chairman, Co-CEO
  - **Richard Kaiser** - CFO, Secretary, Director
  - **Steve Gagnon** - Co-CEO
- The management team utilizes its Virginia Beach, Virginia office for marketing, sales, and customer support.

## Market Presence
- The vitamin and supplement manufacturing industry is worth approximately **$36 billion** with an average annual growth rate of **2.5%**.
- BioForce had **zero customers** during its **2022 and 2023 fiscal years** and is focused on strategies to broaden its customer base, including promotional initiatives aimed at acquiring customers and improving market share.

## Additional Information
- The company operates under significant financial constraints, necessitating reliance on loans and financial support from its executives to cover operational expenses.
- The overall operational strategy and revenue generation plans are critical for the company’s ability to remain a going concern, given its continuous operational losses and very limited cash reserves.

This detailed overview summarizes BioForce Nanosciences Holdings, Inc.'s key operational and financial aspects as of the end of 2023.

BIOFORCE NANOSCIENCES HOLDINGS, INC.

10-K / April 8, 2025

10-K / April 1, 2024

10-K / April 8, 2025

Company Summary: BioForce Nanosciences Holdings, Inc.

Business Focus

Current Mission and Business Model

Product Offerings

Marketing Strategies

Company Operations and Infrastructure

Financial Overview (as of December 31, 2024)

Additional Notes